Clinical Trial Update: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. [Phase 3]

View source ↗

Summary

Phase 3 trial of romiplostim for chemotherapy-induced thrombocytopenia in adults with lymphoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia
• Lymphoma

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Chemotherapy-induced Thrombocytopenia | Phase 3 | Status: WITHDRAWN